Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
36.49
-0.44 (-1.19%)
Aug 14, 2025, 10:23 AM - Market open
Marinus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Marinus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $73.67, which forecasts a 101.89% increase in the stock price over the next year. The lowest target is $54 and the highest is $86.
Price Target: $73.67 (+101.89%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 4 | 4 |
| Buy | 6 | 7 | 7 | 7 | 6 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $75 → $77 | Buy | Maintains | $75 → $77 | +111.02% | Aug 12, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $81 → $83 | Buy | Maintains | $81 → $83 | +127.46% | Aug 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +105.54% | Jul 17, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $80 → $81 | Buy | Maintains | $80 → $81 | +121.98% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +105.54% | Jul 8, 2025 |
Financial Forecast
Revenue This Year
1.05B
from 627.24M
Increased by 66.76%
Revenue Next Year
1.60B
from 1.05B
Increased by 52.58%
EPS This Year
-0.57
from -0.97
EPS Next Year
0.59
from -0.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 1.9B | 2.9B | ||
| Avg | 1.0B | 1.6B | 2.2B | ||
| Low | 906.6M | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 90.2% | 85.4% | 79.8% | ||
| Avg | 66.8% | 52.6% | 37.7% | ||
| Low | 44.5% | 14.6% | 9.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.22 | 1.40 | 1.35 | ||
| Avg | -0.57 | 0.59 | 1.05 | ||
| Low | -1.10 | 0.12 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 128.5% | ||
| Avg | - | - | 77.8% | ||
| Low | - | - | 50.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.